nach oben

Journal of Clinical Immunology

Erschienen in:

02.04.2016

The FcγR/IgG Interaction as Target for the Treatment of Autoimmune Diseases

verfasst von: Peter Sondermann

Erschienen in: Journal of Clinical Immunology | Sonderheft 1/2016

Einloggen, um Zugang zu erhalten

Abstract

FcγRs are a crucial component of the antibody response as they mediate the cellular effector functions in response to IgG-containing immune complexes (ICs). Therefore, they also play a central role in the pathogenesis of autoimmune diseases which offers an attractive option to specifically target this class of molecules and their interaction with IgG for treatment of immune disorders. In detail, two strategies are discussed in this article. SM101, a soluble FcγR that is already in clinical development competes with the interaction of IgG with membrane FcγRs. Oppositely, SM201 recruits the inhibitory FcγRIIB for a broad down-modulation of the immune system. The presented approaches for the treatment of autoimmune diseases have the potential be more efficacious with fewer side effects than the currently used therapeutic options.

Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. Nat Rev Immunol. 2008;8:34–47.CrossRefPubMed

Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014. doi:10.3389/fimmu.2014.00520.PubMedPubMedCentral

Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov. 2009;8:226–34.CrossRefPubMed

Schmidt RE, Gessner JE. Fc receptors and their interaction with complement in autoimmunity. Immunol Lett. 2005;100:56–67.CrossRefPubMed

Pricop L, Redecha P, Teillaud J-L, Frey J, Fridman WH, Sautes-Fridman C, et al. Differential modulation of stimulatory and inhibitory Fc receptors on human monocytes by Th1 and Th2 cytokines. J Immunol. 2001;166:531–7.CrossRefPubMed

Takai T. Roles of Fc receptors in autoimmunity. Nat Rev Immunol. 2002;2:580–92.PubMed

van de Winkel JG, Capel PJ. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today. 1993;14:215–21.CrossRefPubMed

de la Salle C, Esposito-Farese M-E, Bieber T, Moncuit J, Morales M, Wollenberg A, et al. Release of soluble FcgammaRII/CD32 molecules by human Langerhans cells: a subtle balance between shedding and secretion? J Investig Dermatol. 1992;99:15S–7S.CrossRefPubMed

Rappaport EF, Cassel DL, Walterhouse DO, McKenzie SE, Surrey S, Keller MA, et al. A soluble form of the human Fc receptor Fc gamma RIIA: cloning, transcript analysis and detection. Exp Hematol. 1993;21:689–96.PubMed

10.

Calvo CF, Watanabe S, Mètivier D, Senik A. Human monocyte cell line (U937) releases suppressive IgG-binding factor(s). Eur J Immunol. 1986;16:25–30.CrossRefPubMed

11.

Bazil V, Strominger JL. Metalloprotease and serine protease are involved in cleavage of CD43, CD44, and CD16 from stimulated human granulocytes. Induction of cleavage of L-selectin via CD16. J Immunol. 1994;152:1314–22.PubMed

12.

Fridman WH, Golstein P. Immunoglobulin-binding factor present on and produced by thymus-processed lymphocytes (T cells). Cell Immunol. 1974;11:442–55.CrossRefPubMed

13.

Ierino FL, Powell MS, McKenzie IF, Hogarth PM. Recombinant soluble human Fc gamma RII: production, characterization, and inhibition of the Arthus reaction. J Exp Med. 1993;178:1617–28.CrossRefPubMed

14.

Varin N, Sautès C, Galinha A, Even J, Hogarth PM, Fridman WH. Recombinant soluble receptors for the Fcγ portion inhibit antibody productionin vitro. Eur J Immunol. 1989;19:2263–8.CrossRefPubMed

15.

Sautès C, Galinha A, Bouchard C, Mazières N, Spagnoli R, Fridman WH. Recombinant soluble Fcγ receptors: production, purification and biological activities. J Chromatogr B Biomed Sci Appl. 1994;662:197–207.CrossRef

16.

Watanabe H, Sherris D, Gilkeson GS. Soluble CD16 in the treatment of murine lupus nephritis. Clin Immunol Immunopathol. 1998;88:91–5.CrossRefPubMed

17.

Galon J, Bouchard C, Fridman WH, Sautès C. Ligands and biological activities of soluble Fcγ receptors. Immunol Lett. 1995;44:175–81.CrossRefPubMed

18.

Sondermann P, Jacob U. Human Fc gamma receptor IIb expressed in Escherichia coli reveals IgG binding capability. Biol Chem. 1999;380:717–21.CrossRefPubMed

19.

Sondermann P, Jacob U, Kutscher C, Frey J. Characterization and crystallization of soluble human Fcγ receptor II (CD32) isoforms produced in insect cells. Biochemistry. 1999;38:8469–77.CrossRefPubMed

20.

Maenaka K, van der Merwe PA, Stuart DI, Jones EY, Sondermann P. The human low affinity Fcgamma receptors IIa, IIb, and III bind IgG with fast kinetics and distinct thermodynamic properties. J Biol Chem. 2001;276:44,898–904.CrossRef

21.

Sondermann P, Huber R, Jacob U. Crystal structure of the soluble form of the human Fcgamma -receptor IIb: a new member of the immunoglobulin superfamily at 1.7 A resolution. EMBO J. 1999;18:1095–103.CrossRefPubMedPubMedCentral

22.

Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-Å crystal structure of the human IgG1 Fc ragment–FcγRIII complex. Nature. 2000;406:267–73.

23.

Werwitzke S, Trick D, Sondermann P, Kamino K, Schlegelberger B, Kniesch K, et al. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc receptor II (CD32). Ann Rheum Dis. 2008;67:154–61.CrossRefPubMed

24.

Magnusson SE, Andrén M, Nilsson KE, Sondermann P, Jacob U, Kleinau S. Amelioration of collagen-induced arthritis by human recombinant soluble FcγRIIb. Clin Immunol. 2008;127:225–33.CrossRefPubMed

25.

Iwata H, Pipi E, Möckel N, Sondermann P, Vorobyev A, Beek NV, et al. Recombinant soluble CD32 suppresses disease progression in experimental epidermolysis bullosa acquisita. J Investig Dermatol. 2015;135:916–9.CrossRefPubMed

26.

Smith KGC, Clatworthy MR. FcγRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol. 2010;10:328–43.CrossRefPubMedPubMedCentral

27.

Tillmanns S, Sondermann P, Schrödter A, Schubert C, Nilius S, Buckel P. Soluble Fc-gamma IIb receptor SM101 as potential therapy in autoimmune diseases – results from a Phase 0/Ia clinical trial in healthy volunteers. Ann Rheum Dis. 2011;70:618.

28.

Konstaninova TS, Leonidovna IV, Hellmann A, Kyrcz-Krzemien S, Tillmanns S, Sondermann P, et al. Interim results from a phase Ib/IIa clinical trial with the soluble Fc-gamma IIb receptor SM101 for the treatment of primary immune thrombocytopenia. Blood. 2012;120:3388.

29.

Tillmanns S, Kolligs C, DP D’C, Doria A, Hachulla E, Voll RE, et al. SM101, a novel recombinant, soluble, human Fc gamma IIb receptor, in the treatment of systemic lupus erythematosus: results of a double-blind, placebo-controlled multicenter study. Arthritis Rheum. 2014;66:S1238.

30.

Idusogie EE, Presta LG, Gazzano-Santoro H, Totpal K, Wong PY, Ultsch M, et al. Mapping of the C1q binding site on Rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol. 2000;164:4178–84.CrossRefPubMed

31.

Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715–25.CrossRefPubMed

32.

Weflen AW, Baier N, Tang Q-J, Van den Hof M, Blumberg RS, Lencer WI, et al. Multivalent immune complexes divert FcRn to lysosomes by exclusion from recycling sorting tubules. Mol Biol Cell. 2013;24:2398–405.

33.

Sondermann P, Oosthuizen V. X-ray crystallographic studies of IgG-FcγR interactions. Biochem Soc Trans. 2002;30:481–6.CrossRefPubMed

34.

Chen W, Nordstrom J, Burke S, Shah K, Ciccarone V, Li H, et al. Development of human B-lymphocyte targeted bi-specific DART® molecules for the treatment of autoimmune disorders (THER5P. 830). J Immunol. 2014;192(1 Supplement):200–9.

35.

Chu SY, Yeter K, Kotha R, Pong E, Miranda Y, Phung S, et al. Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fcγ receptor IIb inhibitory receptor. Arthritis Rheum. 2014;66:1153–64.CrossRef

36.

Rieth N, Carle A, Müller M, Meer DT, Direnberger C, Pohl T, et al. Characterization of SM201, an anti-hFcγRIIB antibody not interfering with ligand binding that mediates immune complex dependent inhibition of B cells. Immunol Lett. 2014;160:145–50.CrossRefPubMed

37.

Pearse RN, Kawabe T, Bolland S, Guinamard R, Kurosaki T, Ravetch JV. SHIP recruitment attenuates FcγRIIB-induced B cell apoptosis. Immunity. 1999;10:753–60.CrossRefPubMed

38.

Xiang Z, Cutler AJ, Brownlie RJ, Fairfax K, Lawlor KE, Severinson E, et al. FcγRIIb controls bone marrow plasma cell persistence and apoptosis. Nat Immunol. 2007;8:419–29.CrossRefPubMed

Titel: The FcγR/IgG Interaction as Target for the Treatment of Autoimmune Diseases
verfasst von: Peter Sondermann
Publikationsdatum: 02.04.2016
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe Sonderheft 1/2016
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-016-0272-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The FcγR/IgG Interaction as Target for the Treatment of Autoimmune Diseases

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2016

Human Circulating T Follicular Helper Cell Subsets in Health and Disease

Metabolic Control of Plasma Cell Differentiation- What We Know and What We Don't Know

New Insights into IL-10 Dependent and IL-10 Independent Mechanisms of Regulatory B Cell Immune Suppression

Next Generation Sequencing Data Analysis in Primary Immunodeficiency Disorders – Future Directions

Erratum to: The Elements Steering Pathogenesis in IgG-Mediated Alloimmune Diseases

Autoimmunity and Primary Immunodeficiency Disorders

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin